Neomedika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 299,953 | 259,340 | 242,325 | 92,910 | 99,780 | 299,445 | 273,580 | 291,880 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | 110,836 | 93,112 | 54,617 | 26,207 | 29,150 | 132,248 | 152,363 | 145,786 |
| Equity | 125,053 | 218,165 | 272,782 | 298,989 | 210,139 | 342,387 | 377,102 | 182,888 |
| Liabilities | 18,611 | 11,895 | 15,966 | 3,534 | 1,811 | 7,192 | 20,924 | 12,282 |
| Non-current assets | 0 | 0 | 0 | 0 | 21,296 | 18,959 | 15,290 | 11,620 |
| Current assets | 143,662 | 230,060 | 288,748 | 302,523 | 190,654 | 330,620 | 382,344 | 183,336 |
| Total assets | 143,662 | 230,060 | 288,748 | 302,523 | 211,950 | 349,579 | 397,634 | 194,956 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 51,574 | 61,172 | 122,266 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +0.3% | -13.5% | -6.6% | -61.7% | +7.4% | +200.1% | -8.6% | +6.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 77.2% | 40.5% | 18.9% | 8.7% | 13.8% | 37.8% | 38.3% | 74.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 88.6% | 42.7% | 20.0% | 8.8% | 13.9% | 38.6% | 40.4% | 79.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 37.0% | 35.9% | 22.5% | 28.2% | 29.2% | 44.2% | 55.7% | 49.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 299,953 | 155,601 | 121,163 | 46,455 | 49,890 | 149,723 | 136,790 | 145,940 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Neomedika - Social security debts
The company had no debts to Sodra
Neomedika - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Neomedika, UAB (company code 303314087) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €291.9K and net profit of €145.8K, resulting in a profit margin of 49.9%. Revenue increased by 6.7% year on year in 2025 and was 2.5% lower than two years earlier, showing a broadly stable top line after the 2024 dip. Profit remained strong across the period, rising from €132.2K in 2023 to €152.4K in 2024 before easing slightly to €145.8K in 2025. At year-end 2025, total assets stood at €195.0K, equity at €182.9K and liabilities at €12.3K, indicating a very high equity share in the balance sheet. Key efficiency ratios were strong, with ROE at 79.7%, ROA at 74.8%, debt-to-equity at 0.07 and asset turnover at 1.50x. Revenue per employee was €145.9K and profit per employee was €72.9K, pointing to solid productivity.